• 1
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421430.
  • 2
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. HEPATOLOGY 2003; 37: 429442.
  • 3
    Carr BI, Van Thiel DH. Hormonal manipulation of human hepatocellular carcinoma. A clinical investigative and therapeutic opportunity. J Hepatol 1990; 11: 287289.
  • 4
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 16091618.
  • 5
    Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26: 6668.
  • 6
    Martinez-Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702706.
  • 7
    Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003; 18: 267272.
  • 8
    Touraine RL, Bertrand Y, Foray P, Gilly J, Philippe N. Hepatic tumours during androgen therapy in Fanconi anaemia. Eur J Pediatr 1993; 152: 691693.
  • 9
    See KL, See M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 7379.
  • 10
    Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone: estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000; 60: 51065110.
  • 11
    Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001; 93: 16441651.
  • 12
    Hinchliffe SA, Woods S, Gray S, Burt AD. Cellular distribution of androgen receptors in the liver. J Clin Pathol 1996; 49: 418420.
  • 13
    Eagon PK, Elm MS, Epley MJ, Shinozuka H, Rao KN. Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterology 1996; 110: 11991207.
  • 14
    Granata O, Carruba G, Montalto G, Miele M, Bellavia V, Modica G, et al. Altered androgen metabolism eventually leads hepatocellular carcinoma to an impaired hormone responsiveness. Mol Cell Endocrinol 2002; 193: 5158.
  • 15
    Matsumoto T, Takagi H, Mori M. Androgen dependency of hepatocarcinogenesis in TGFalpha transgenic mice. Liver 2000; 20: 228233.
  • 16
    Maruyama S, Nagasue N, Dhar DK, Yamanoi A, El-Assal ON, Satoh K, et al. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res 2001; 7: 20962104.
  • 17
    Yu LQ, Nagasue N, Yamaguchi M, Chang YC. Effects of castration and androgen replacement on tumour growth of human hepatocellular carcinoma in nude mice. J Hepatol 1996; 25: 362369.
  • 18
    Nagasue N, Yu L, Yukaya H, Kohno H, Nakamura T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 1995; 82: 542547.
  • 19
    Boix L, Castells A, Bruix J, Sole M, Bru C, Fuster J, et al. Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 1995; 22: 616622.
  • 20
    Ng IOL, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 1997; 92: 13551358.
  • 21
    Chao Y, Chan WK, Huang YS, Teng HC, Wang SS, Lui WY, et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 1996; 77: 635639.
  • 22
    Gupta S, Korula J. Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 1988; 10: 647650.
  • 23
    Forbes A, Wilkinson ML, Iqbal MJ, Johnson PJ, Williams R. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5-alpha-dihydrotestosterone. Eur J Cancer Clin Oncol 1987; 23: 16591664.
  • 24
    Guéchot J, Peigney N, Ballet F, Vaubourdolle M, Giboudeau J, Poupon R. Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. HEPATOLOGY 1989; 10: 346348.
  • 25
    Falkson G, Ansell S. Phase II trial of buserelin in hepatocellular carcinoma. Eur J Cancer Clin Oncol 1989; 25: 13391340.
  • 26
    Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Nat Cancer Inst 2000; 92: 20232028.
  • 27
    Dalesio O, van Tinteren H, Clarke M, Peto R, Schroder FH, Dechering I, et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 14911498.
  • 28
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11911194.
  • 29
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457481.
  • 30
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A Stat Soc 1972; 135: 185189.
  • 31
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B Stat Methodol 1972; 34: 187220.
  • 32
    Therneau TM, Grambsch PM. Testing proportional hazards. In: TherneauTM, GrambschPM, eds. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag, 2000: 127152.
  • 33
    Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361372.
  • 34
    Chevret S, Trinchet JC, Mathieu M, Abou Rached A, Beaugrand M, Chastang C, Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31: 133141.
  • 35
    Langenstroer P, Porter HJ 2nd, McLeod DG, Thrasher JB. Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol 2004; 171: 684686.
  • 36
    Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. HEPATOLOGY 1995; 21: 15351542.
  • 37
    Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma. Results of a European organization for research and treatment of cancer multicentric double-blind trial. J Clin Oncol 1998; 16: 411417.
  • 38
    Tavian D, De Petro G, Pitozzi A, Portolani N, Giulini SM, Barlati S. Androgen receptor mRNA under-expression in poorly differentiated human hepatocellular carcinoma. Histol Histopathol 2002; 17: 11131119.
  • 39
    Yu LQ, Kubota H, Imai K, Yamaguchi M, Nagasue N. Heterogeneity in androgen receptor levels and growth response to dihydrotestosterone in sublines derived from human hepatocellular carcinoma line (KYN-1). Liver 1997; 17: 3540.
  • 40
    Yeh SH, Chang CF, Shan WY, Chen YW, Hsu HC, Lee PH, et al. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 2002; 62: 43464351.
  • 41
    Yu MW, Yang YC, Yang SY, Chang HC, Liaw YF, Lin SM, et al. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. HEPATOLOGY 2002; 36: 156163.
  • 42
    Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafoco P, et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. HEPATOLOGY 1998; 27: 983988.
  • 43
    Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 3339.
  • 44
    Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, et al. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199: 451455.
  • 45
    Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Unluhizarci K. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 1999; 18: 137140.
  • 46
    Kitamura T, Tanaka K, Morita K, Saito S, Kiba T, Numata K, et al. Dehydroepiandrosterone (DHEA) facilitates liver regeneration after partial hepatectomy in rats. Life Sci 1999; 65: 17471756.
  • 47
    Vizzotto L, Vartemati M, Marinello E, Leoncini R, Pagani R, Pizzichini M. Effect of testosterone on purine metabolism and morphometric parameters in the rat liver. Mol Cell Endocrinol 1996; 119: 123127.
  • 48
    Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002; 97: 16741681.
  • 49
    Pu YS, Liu CM, Kao JH, Chen J, Lai MK. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol 1999; 36: 293297.
  • 50
    Oberhammer F, Nagy P, Tiefenbacher R, Froschl G, Bouzahzah B, Thorgeirsson SS, et al. The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. HEPATOLOGY 1996; 23: 329337.